GlassScriptPhysician profile
Julianne Macmullen
NPI 1053044107
$5,016.16
in general payments reported to CMS, 2019-2025
40 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $211 · 2023: $2,859 · 2024: $1,265 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,429 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,428.73 |
| Education | $376.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $2,023.60 | 2022-2024 | Cabometyx |
| Collegium Pharmaceutical, INC. | $494.49 | 2024-2025 | Belbuca, Xtampza |
| Daiichi Sankyo INC. | $287.71 | 2022-2024 | Enhertu, Injectafer |
| Incyte Corporation | $277.97 | 2023-2024 | Monjuvi, Jakafi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $258.85 | 2022-2025 | Lynparza, Tagrisso, Enhertu |
| Lilly USA, LLC | $137.94 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Abbvie INC. | $133.77 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $126.43 | 2022-2025 | |
| Astellas Pharma US INC | $118.55 | 2023-2024 | Padcev |
| Glaxosmithkline, LLC. | $104.08 | 2023-2024 | Zejula, Jemperli |
| Celgene Corporation | $88.38 | 2023-2024 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $81.63 | 2023-2024 | Libtayo |
| Sobi, INC | $81.38 | 2023-2024 | |
| Pharmaessentia USA Corporation | $69.84 | 2023-2024 | Besremi |
| Springworks Therapeutics, INC. | $58.08 | 2024 | Ogsiveo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.20 | 2022-2023 | Keytruda |
| Janssen Biotech, INC. | $53.94 | 2023-2024 | Imbruvica, Carvykti, Rybrevant |
| Pharmacosmos Therapeutics INC. | $53.28 | 2024 | Monoferric |
| Medtronic, INC. | $36.98 | 2025 | Synchromedii, Inceptiv |
| E.R. Squibb & Sons, L.L.C. | $36.33 | 2023-2024 | |
| Stemline Therapeutics INC. | $35.49 | 2023-2024 | Elzonris, Orserdu |
| Seagen INC. | $34.56 | 2023 | Padcev |
| Pfizer INC. | $31.74 | 2025 | |
| G1 Therapeutics, INC. | $24.22 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $22.95 | 2023 | Epkinly, Imbruvica |
| Deciphera Pharmaceuticals INC. | $22.89 | 2025 | Qinlock, Romvimza |
| Amgen INC. | $22.83 | 2023 | Vectibix, Xgeva, Nplate |
| Taiho Oncology, INC. | $22.78 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.91 | 2024 | Onivyde |
| Servier Pharmaceuticals LLC | $20.39 | 2024 | |
| Beigene USA, INC. | $20.20 | 2024 | Brukinsa |
| Kite Pharma, INC. | $19.73 | 2023 | |
| Gilead Sciences, INC. | $19.71 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $18.92 | 2025 | |
| Curonix LLC | $18.92 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Genmab U.S., INC. | $18.51 | 2023 | Epkinly |
| Novo Nordisk INC | $16.85 | 2025 | |
| Novocure INC. | $16.48 | 2023 | Optune |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.79 | 2024 | Gilotrif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julianne Macmullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.